Back

Targeted anticoagulant reversal, unintended consequences: lessons from andexanet alfa

European Heart Journal - Cardiovascular Pharmacotherapy

13 March 2026
Organised by: Logo
Read full article
ESC Journals

Contributors

Jerrold H Levy
Jerrold H Levy

Author

Duke University Health System Durham , United States of America

Joseph R Shaw
Joseph R Shaw

Author

You may be interested in
thumbnail
Congress Presentation
Reversal agents to improve safety in patients treated with direct oral anticoagulants (DOACs).
26 August 2022
thumbnail
Webinar
Cancer associated thrombosis: have DOACs changed daily practice?
21 September 2021
thumbnail
Congress Session
How can targeting FXI(a) advance antithrombotic therapy for stroke prevention?
27 August 2023
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?
14 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources